Radotinib - Il-Yang

Drug Profile

Radotinib - Il-Yang

Alternative Names: IY-5511; IY5511HCl; Radotinib hydrochloride; Supect

Latest Information Update: 11 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Il-Yang
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Bcr-abl tyrosine kinase inhibitors; Platelet-derived growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic myeloid leukaemia

Most Recent Events

  • 13 Jul 2018 Il-Yang completes a phase I/II trial for Chronic myeloid leukaemia (Second-line therapy or greater) in India, South Korea, and Thailand (PO) (NCT01602952)
  • 25 Jun 2018 Il-Yang initiates a phase III trial for Chronic myeloid leukaemia (Second-line therapy or greater) in South Korea (PO) (NCT03459534)
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top